Journal Mobile Options
Table of Contents
Vol. 15, No. 1, 2003
Issue release date: December 2002
Dement Geriatr Cogn Disord 2003;15:1–5

APOE Genotype, Memory Test Performance, and the Risk of Alzheimer’s Disease in the Canadian Study of Health and Aging

Klages J.D. · Fisk J.D. · Rockwood K.
Departments of aPsychology, bPsychiatry and cMedicine, Dalhousie University, and dDepartment of Psychology, Queen Elizabeth II Health Sciences Centre, Halifax, Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: This study examined the relation between two risks for Alzheimer’s disease (AD): the apolipoprotein (APOE) ε4 allele and poor memory test performance. Methods: In the Canadian Study of Health and Aging (CSHA), a 5-year longitudinal population-based study that screened and followed over 10,000 participants, 2,914 had an initial clinical assessment and 1,624 had APOE genotype testing. All participants were categorized as having no cognitive impairment, cognitive impairment but no dementia, or dementia at both baseline and follow-up. We examined those (n = 209) with a complete neuropsychological assessment at baseline and no evidence of cognitive impairment who had either APOE ε3/ε3 or ε3/ε4 genotypes and who had a clinical consensus diagnosis of either no cognitive impairment or AD at follow-up. Delayed free recall memory was evaluated at CSHA-1 with the Buschke Cued Recall Test (BCRT). Results: The risk of AD at follow-up was increased for participants with an APOE ε3/ε4 genotype when memory test performance was not considered, but logistic regression demonstrated that a model which also considered baseline memory test performance was more predictive of AD. In the more complete model, reduced BCRT free recall scores were associated with an increased risk of AD, whereas the risk associated with the APOE ε3/ε4 genotype was no longer significant. Conclusions: For those with no evidence of cognitive impairment, drawn from a population-based sample of elderly persons, the APOE ε3/ε4 genotype was only associated with an increased risk of AD after 5 years if their memory test performance was relatively poor at baseline. Regardless of the APOE genotype, and in the absence of clinical evidence of cognitive impairment, reduced scores on a test of delayed free recall at baseline was associated with an increased risk of AD after 5 years.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Rebeck GW, Hyman BT: Apolipoprotein E and Alzheimer disease; in Terry RD, Katzman R, Bick KL, Sisodia SS (eds): Alzheimer Disease, ed 2. Philadelphia, Lippincott Williams & Wilkins, 1999, pp 339–346.
  2. APOE and Alzheimer Disease Meta Analysis Consortium: Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA 1997;278:1349–1356.
  3. Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko HJ, McDowell I: Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349:1793–1796.
  4. Peterson RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  5. Ritchie K, Touchon J: Mild cognitive impairment: Conceptual basis and current nosological status. Lancet 2000;355:225–228.
  6. Tierney MC, Szalai JP, Snow WG, Fisher RH, Nores A, Nadon G, Dunn E, St George-Hyslop PH: Prediction of probable Alzheimer’s disease in memory-impaired patients: A prospective longitudinal study. Neurology 1996;46:661–665.
  7. Elias MF, Beiser A, Wolf PA, Au R, White RF, D’Agostino RB: The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol 2000;57:808–813.
  8. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Bäckman L: The course of cognitive impairment in preclinical Alzheimer disease: Three- and 6-year follow-up of a population-based sample. Arch Neurol 2000;57:839–844.
  9. Reed T, Carmelli D, Swan GE, Breitner JC, Welsh KA, Jarvik GP, Beeb S, Auwerx J: Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E ε4 allele. Arch Neurol 1994;51:1189–1192.
  10. Staehelin HB, Perrig-Chiello P, Mitrache C, Miserez AR, Perrig WJ: Apolipoprotein E genotypes and cognitive functions in healthy elderly persons. Acta Neurol Scand 1999;100:53–60.
  11. Bondi MW, Salmon DP, Monsch AU, Galasko D, Butters N, Klauber MR, Thal L, Saitoh T: Episodic memory changes are associated with the APOE-ε4 allele in nondemented older adults. Neurology 1995;45:2203–2206.
  12. Smith GE, Bohac DL, Waring SC, Kokmen E, Tanglos EG, Ivnik RJ, Petersen RC: Apolipoprotein E genotype influences cognitive ‘genotype’ in patients with Alzheimer’s disease but not in healthy control subjects. Neurology 1998;50:355–362.
  13. Tierney MC, Szalai JP, Snow WG, Fisher RH, Tsuda T, Chi H, McLachlan, St George-Hyslop PH: A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996;46:149–154.
  14. Canadian Study of Health and Aging Working Group: Canadian Study of Health and Aging: Study methods and prevalence of dementia. Can Med Assoc J 1994;150:899–913.
  15. Canadian Study of Health and Aging Working Group: The incidence of dementia in Canada. Neurology 2000;55:66–73.
  16. McDowell I, Aylesworth R, Stewart M, Hill G, Lindsay J: Study sampling in the Canadian Study of Health and Aging. Int Psychogeriatr 2001;13:19–28.

    External Resources

  17. Teng EL, Chui HC: The Modified Mini-Mental State (3MS) Examination. J Clin Psychiatry 1987;48:314–318.
  18. McLeod DA, Arnott B, Gaudreault N, Boudreau S, Sevigny P: A comparison of two methods for routine, accurate determination of apolipoprotein E genotypes. Alzheimer’s Rep 1998;1:211–215.
  19. Yee IM, Feldman H, Sadovnick D: The effect of apolipoprotein E genotypes in Alzheimer’s disease: Data from the Canadian Study of Health and Aging. Neurobiol Aging 2000;21(1S):S36–S37.
  20. Graham JE, Rockwood K, Beattie BL, McDowell I, Eastwood R, Gauthier S: Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging. Neuroepidemiology 1996;15:246–256.
  21. Tuokko H, Kristjansson E, Miller J: Neuropsychological detection of dementia: An overview of the neuropsychological component of the Canadian Study of Health and Aging. J Clin Exp Neuropsychol 1995;17:352–373.
  22. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3, revised. Washington, American Psychiatric Association, 1987.
  23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  24. Tuokko H, Crockett D: Cued recall and memory disorders in dementia. J Clin Exp Neuropsychol 1989;11:278–294.
  25. Petersen RC, Smith G, Kokmen E, Ivnik RJ, Tangalos EG: Memory function in normal aging. Neurology 1992;42:396–401.
  26. Tuokko H, Vernon-Wilkinson R, Weir J, Beattie L: Cued recall and early identification of dementia. J Clin Exp Neuropsychol 1991;13:871–879.
  27. Collie A, Maruff P, Shafiq-Antonacci R, Smith M, Hallup M, Schofield PR, Masters CL, Currie J: Memory decline in healthy older people: Implications for identifying mild cognitive impairment. Neurology 2001;56:1533–1538.
  28. Petersen RC, Stevens JC, Ganguli M, Tanglos EG, Cummings JL, DeKosky ST: Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Neurology 2001;56:1133–1142.
  29. Fisk JD, Sadovnik AD, Cohen CA, Gauthier S, Dossetor J, Eberhart A, LeDuc L: Ethical guidelines of the Alzheimer Society of Canada. Can J Neurol Sci 1998;25:242–248.
  30. AGS Ethics Committee: Genetic testing for late-onset Alzheimer’s disease. J Am Geriatr Soc 2001;49:225–226.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50